Stock Screener App

Gratuito -

Installare

3.91

0.38% -0.010

Sab Biotherapeutics Inc (SABS)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione

Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial - TipRanks

Breakthrough T1D funds PRISE-hATG to study SAB-142 in Stage 3 type 1 diabetes - TradingView

Grant backs SAB Biotherapeutics (NASDAQ: SABS) PRISE-hATG Stage 3 T1D trial - Stock Titan

Breakthrough T1D backs SAB-142 study beyond the first 100 days - Stock Titan

Wall Street Analysts Lift SAB Biotherapeutics Stock Over Diabetes Drug - HarianBasis.co

Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Yahoo Finance

SAB Biotherapeutics, Inc. Warrant 2021-22.10.26 on SAB Biotherap Financial Disclosures & SEC Filings - TradingView

Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView

Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Yahoo Finance

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Index - marketscreener.com

SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Microcap Value Benchmark Index - marketscreener.com

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 2000 Value Benchmark - marketscreener.com

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell Microcap Index - marketscreener.com

SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to Russell 3000E Value Benchmark - marketscreener.com

SAB Biotherapeutics, Inc.(NasdaqCM:SABS) added to Russell Small Cap Completeness Index - marketscreener.com

Price to sales forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView

Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABSW - TradingView

Form 4 SAB Biotherapeutics Inc For: 26 June By Investing.com - Investing.com South Africa

Enterprise value to EBITDA forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView

Price to book forward of SAB Biotherapeutics, Inc. – NASDAQ:SABS - TradingView

[Form 4] SAB Biotherapeutics, Inc. Insider Trading Activity - Stock Titan

SAB Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:SABS) - TradingView

SABS Forecast — Price Target — Prediction for 2027 - TradingView

SAB Biotherapeutics (SABS) Short Interest & Short Float | Updated Jun 2026 $SABS - MarketBeat

Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 By Investing.com - Investing.com South Africa

Barclays Initiates SAB Biotherapeutics at Overweight With $13 Price Target - marketscreener.com

Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 - Investing.com

SAB Biotherapeutics Inc (SABS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey

Citi Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $11 - Moomoo

SAB Biotherapeutics (SABS) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr

SAB Biotherapeutics Inc (SABS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

SAB Biotherapeutics Inc (SABS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

SAB Biotherapeutics Inc (SABS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

SAB Biotherapeutics shareholders elect directors and approve auditor at annual meeting - Investing.com UK

SAB Biotherapeutics, Inc. 8-K SEC Filing Details for June 18, 2026: Company Information & Nasdaq Listing - Minichart

SAB Biotherapeutics Shareholders Back Board and Auditor - TipRanks

SAB Biotherapeutics (NASDAQ: SABS) investors back board slate and auditor - Stock Titan

SAB Biotherapeutics Inc (SABS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

SAB Biotherapeutics Inc (SABS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

SAB Biotherapeutics Inc (SABS) Valuation: PE, PB & Fair Value Analysis - TradingKey

SAB Biotherapeutics Inc (SABSW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

SAB Biotherapeutics Inc (SABSW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

SAB Biotherapeutics Inc (SABSW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

SAB Biotherapeutics Inc (SABSW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

SAB Biotherapeutics Inc (SABSW) Valuation: PE, PB & Fair Value Analysis - TradingKey

SAB Biotherapeutics Inc (SABSW) Institutional Confidence - TradingKey

SABS Maintained by Chardan Capital -- Price Target Raised to $16 - GuruFocus

SAB Biotherapeutics Inc (SABSW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

SAB Biotherapeutics Inc (SABSW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

SAB Biotherapeutics Inc (SABSW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Chardan Capital Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Raises Target Price to $16 - Moomoo

SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jefferies raises SAB Biotherapeutics price target on FDA approval By Investing.com - Investing.com South Africa

SABS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10.00 - GuruFocus

H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo

INSM

$113.07

1.38%

ROIV

$35.27

0.23%

RPRX

$57.70

1.38%

MRNA

$78.94

3.59%

ONC

$305.62

1.15%

RVMD

$190.47

0.31%

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters